PfSPZ-LARC2 Vaccine

BIOLOGICAL2 trials

Sponsors

Sanaria Inc.

Conditions

Malaria FalciparumMalaria Infection

Phase 1

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

CompletedNCT06652737

Sanaria Inc.Malaria Falciparum, Malaria Infection

Start: 2025-03-04End: 2026-02-18Updated: 2026-04-16

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

RecruitingNCT06862453

Sanaria Inc.Malaria Falciparum

Start: 2026-04-01End: 2026-12-30Target: 58Updated: 2026-04-16